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Background: Redback spiders (Latrodectus hasselti) (RBSs) are venomous spiders that have recently spread to Asia
from Australia. Since the first case report in 1997 (Osaka), RBS bites have been a clinical and administrative issue in
Japan; however, the clinical characteristics and effective treatment of RBS bites, particularly outside Australia remains
unclear. This study aimed to elucidate the clinical characteristics of RBS bites and to clarify the effectiveness of the
administration of antivenom for treatment.
Methods: We performed a retrospective questionnaire survey from January 2009 to December 2013 to determine
the following: patient characteristics, effect of antivenom treatment, and outcomes. To clarify the characteristics of
patients who develop systemic symptoms, we compared patients with localized symptoms and those with
systemic symptoms. We also examined the efficacy and adverse effects in cases administered antivenom.
Results: Over the 5-year study period, 28 patients were identified from 10 hospitals. Of these, 39.3% were male and
the median age was 32 years. Bites most commonly occurred on the hand, followed by the forearm. Over 80% of
patients developed local pain and erythema, and 35.7% (10 patients) developed systemic symptoms. Baseline
characteristics, vital signs, laboratory data, treatment-related factors, and outcome were not significantly different
between the localized and systemic symptoms groups. Six patients with systemic symptoms received antivenom, of
whom four experienced symptom relief following antivenom administration. Premedication with an antihistamine
or epinephrine to prevent the adverse effects of antivenom was administered in four patients, which resulted in no
anaphylaxis. One out of two patients who did not receive premedication developed a mild allergic reaction after
antivenom administration that subsided without treatment.
Conclusions: Approximately one third of cases developed systemic symptoms, and antivenom was administered
effectively and safely in severe cases. Further research is required to identify clinically applicable indications for
antivenom use.
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Redback spiders (Latrodectus hasselti) (RBSs) are venom-
ous spiders that produce the neurotoxin (alpha-latrotoxin)
[1]. The adult female is characterized by a spherical black
body with a prominent red stripe on the upper side of the
abdomen (Figure 1a). Females have a body length of ap-
proximately 10 mm, and the male measures only 3–4 mm
[2]. Although widely distributed in Australia, it has re-
cently spread to Southeast and West Asia [3-5].* Correspondence: hifumitoru@gmail.com
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unless otherwise stated.Symptoms of RBS bites are usually mild and localized,
such as local pain and erythema. However, fatal cases
had been reported before the development of antivenom
(Figure 1b), which is manufactured by the immunization
of horses [6,7]. Since the first case reported in Osaka in
1997, RBS bites have been a clinical and administrative
issue in Japan [8,9]. Despite this, the clinical characteris-
tics and optimal treatment of RBS bites, particularly out-
side Australia remain unknown.
Therefore, this study aimed to elucidate the clinical
characteristics of RBS bites and the factors associated
with developing systemic symptoms. We also aimed toLtd.; This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
(a) (b)
Figure 1 Redback spider and an example of the antivenom. (a) The left image shows a female Redback spider. (b) The right image depicts
an example of the antivenom used for Redback spider bites.
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venom for treatment.Methods
This is a retrospective observational study. The institu-
tional review board of the Kagawa university hospital ap-
proved this cross-sectional, survey-based study (Heisei
26-029).Patients and setting
We prepared a questionnaire to examine the clinical
characteristics of RBS bites in Japan. The questionnaires
consisted of initial screening survey (phase I survey) and
survey for clinical data (phase II survey). The initial
screening questionnaire (phase I survey) was sent to 470
sentinel medical institutions originally used for the
national surveillance for infections of antimicrobial
resistant bacteria and severe influenza to cover major hos-
pitals in all areas of Japan, such as University Hospitals,
National Hospitals, and Red Cross Hospitals. The ques-
tionnaire was about the absence or presence of patients
with RBS bites and was sent in January 2014 and collected
by March 2014. Completed questionnaires were received
from 297 (63.2%) sentinel medical institutions, with four
hospitals that responded to having treated patients with
RBS bites.
The questionnaire for obtaining clinical data (phase II
survey) was sent to those four hospitals that responded
to having treated patients with RBS bites in the phase I
survey. We also sent the questionnaire (phase II survey)
to seven other hospitals that possessed antivenom
against RBS in May 2014. The surveillance period of thequestionnaire spanned 5 years, i.e., from January 2009 to
December 2013.
Data collection
The following parameters were recorded: age, gender, date
of injury, bite location, clinical symptoms (local pain, ery-
thema, edema, sweating, headache, nausea, abdominal
numbness, systemic pain, and others), vital signs (systolic
blood pressure and body temperature), laboratory data
(white blood cell and platelet counts, creatinine kinase,
and aspartate aminotransferase), treatment-related factors
(analgesics and antivenom), effectiveness and adverse ef-
fects of antivenom, and outcomes (days in hospital, days
in intensive care unit (ICU), and in-hospital mortality).
Diagnosis of RBS bites and definition of systemic
symptoms
No definite diagnostic criteria exist. Diagnosis of RBS bites
was based on either the patient’s history or the positive
identification of RBS presented by the patient. Systemic
effects were considered to include sweating, headache, nau-
sea, abdominal numbness, systemic pain, fever, hyperten-
sion, parasthesia, fasciculations, and cardiac effects [10]. In
the current study, patients with systemic symptoms were
defined as those who developed at least the abovemen-
tioned one symptom.
Treatment of RBS bites
The definitive treatment for RBS envenomation in
Australia is the use of a specific RBS antivenom produced
by Commonwealth Serum Laboratories (CSL) [11]. Be-
cause RBS antivenom has not been approved by the Min-
istry of Health, Labour and Welfare in Japan, clinicians
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Australia, the indications for RBS antivenom are patients
with signs of systemic envenomation, those with pain not
controlled with simple analgesia, or for those who require
repeated doses of opiates [12]. In the current survey, the
decision to administer antivenom was made by individual
doctors and was not based on any protocol.
Primary data analysis
Patient characteristics, treatment-related factors, and
outcomes were compared between the localized and the
systemic symptoms groups using Mann-Whitney U test
and the Fisher’s exact test for categorical variables, as
appropriate.
Two-tailed P-values of ≤0.05 were considered statisti-
cally significant. Statistical analysis was performed using
JMP version 11 (SAS, Cary, NC, USA).
Results
Demographic data and clinical characteristics of all study
patients
Over the 5-year study period, 28 patients were identified
from 10 hospitals. The areas where RBS bites were re-
ported were limited to three prefectures: Osaka, Nara,
and Fukuoka (Figure 2). The patient characteristics are
summarized in Table 1; 39.3% were male and the median
age was 32 years. The most common sites for bites wereNara
Osaka
Fukuoka
Figure 2 A map showing the relative locations of cases of redback spthe hand (42.9%) and the forearm (17.9%). Over 80% of
patients developed local pain and erythema, and systemic
symptoms occurred in 10 patients (35.7%). Antivenom
was administered to six patients, four (14.3%) were ad-
mitted to hospital, and one required care at ICU. All pa-
tients recovered without lasting adverse effects.
Comparison between the localized and systemic
symptoms groups
We compared the clinical characteristics between the lo-
calized and systemic symptoms groups to clarify the
characteristics of patients that develop systemic symp-
toms; our results are summarized in Table 2. There were
no significant differences between the two groups in
terms of baseline characteristics, vital signs, laboratory
data, treatment-related factors, and outcomes.
Details of cases who received antivenom
The details of six patients who received antivenom are
summarized in Table 3. Antivenom administration relieved
symptoms in four patients who developed systemic symp-
toms. Premedication with an antihistamine or epinephrine
to prevent the adverse effects of antivenom was adminis-
tered in four patients, which resulted in no anaphylaxis.
One out of two patients who did not receive premedication
developed a mild allergic reaction after antivenom admin-
istration that subsided without treatment.Area from which the 




ider bites: Osaka, Nara, and Fukuoka Prefectures.
Table 1 Population characteristics (n = 28)
Characteristics Values
Age (years) 32 (15.5–56.5)
>65 years 4 (14.3%)
<15 years 6 (21.4%)






Local pain, n (%) 25 (89.2)
Edema, n (%) 13 (46.4)
Erythema, n (%) 24 (85.7)
Systemic symptoms 10 (35.7)
Sweating, n (%) 2 (7.1)
Headache, n (%) 2 (7.1)
Nausea, n (%) 4 (14.8)
Numbness on the abdomen, n (%) 2 (7.1)
Systemic pain, n (%) 2 (7.1)
Others (high grade fever at 39°C light
headedness), n (%)
2 (7.1)
Vital signs on admission
SBP (mmHg) 132 (123–150)
BT (°C) 36.8 (36.4–37.1)
Laboratory data
WBC (/mm3) 9,000 (6,597–9,600)
Platelet count (×104/mm3) 23.6 (17.8–28.9)
CK (IU/L) 156 (73–170)
AST (IU/L) 33 (22–52)
Treatment
Antivenom, n (%) 6 (21.4)
Analgesics, n (%) 8 (28.6)
Outcome
Hospital admission, n (%) 4 (14.3)
ICU admission, n (%) 1 (3.6)
Mortality, n (%) 0 (0)
Data are presented as median (interquartile range, IQR) for continuous
variables and n (percentage) for categorical variables.
SBP systolic blood pressure; BT body temperature; WBC white blood cell;
CK creatine kinase; AST aspartate aminotransferase.
Hifumi et al. Journal of Intensive Care 2014, 2:62 Page 4 of 6
http://www.jintensivecare.com/content/2/1/62Discussion
In the current survey, all 28 cases recovered well. Six
cases received antivenom, of which four had symptom-
atic relief with no serious adverse effects. One out of two
patients who did not receive premedication developed a
mild allergic reaction after antivenom administration thatsubsided without treatment. Notably, 36% of patients
developed systemic symptoms. No significant factors
associated with systemic symptoms were identified.
In Australia, antivenom is recommended for patients
with signs of systemic envenomation. Indeed, those with
severe or systemic symptoms and patients at greater
risk, such as children, pregnant women, and the elderly,
are more likely to receive antivenom [12,13]. Conversely,
no indication has been provided for antivenom use in
clinical practice in Japan. Five out of six cases in the
current survey (four cases with systemic symptoms and
one pediatric case) received antivenom based on the
indications used in Australia. Although four cases out of
ten that developed systemic symptoms recovered with
RBS antivenom, the remaining cases with systemic
symptoms recovered without antivenom. We identified
no cases among pregnant women. Given these facts,
further research is required to identify the appropriate
clinical indications for antivenom use in Japan.
Alpha-latrotoxin causes synaptic vesicle exocytosis
from the presynaptic terminal, via a calcium-dependent
mechanism, leading to the release of catecholamines and
acetylcholine [14]. Therefore, although the primary
impact of the envenomation can be mild, it is assumed
that these substances, together with hypertension
induced by persistent pain, worsen the condition among
both elderly patients with comorbidities and pregnant
women. In such populations, antivenom administration
may be considered.
RBS antivenom is manufactured by the immunization
of horses. Therefore, there is a risk of adverse events such
as anaphylaxis and serum sickness disease [15,16]. In
studies in Australia, allergic reactions to the antivenom
have been rare (<2%) [7]. However, Mamushi antivenom,
which is also manufactured by the immunization of
horses, causes a 2.4%–9% rate of anaphylactic reactions
in Japan [17,18]. In the present study, none of the four
cases that received antivenom with premedication against
anaphylaxis had an adverse reaction. However, one case
that did not receive premedication developed a mild
allergic reaction. Therefore, premedication with an anti-
histamine and/or epinephrine should be used when the
perceived benefit is greater than the risk of adverse
effects.
The serious concern with the current treatment of RBS
bites is that RBS antivenom is not approved by the Minis-
try of Health, Labour and Welfare. Therefore, clinicians
are required to privately import it from Australia. More-
over, in 2013, all imports from Australia were suspended
due to the low production of RBS antivenom by CSL. In
2013, the Ministry of Health, Labour and Welfare of
Japan launched a research group to evaluate the safety
and efficacy of antivenom and to organize and maintain
information on RBS bites [19]. In the group, domestic
Table 2 Comparison between the groups with local and systemic symptoms
Limited to local (n = 18) Systemic (n = 10) P value
Age (years) 30.5 (10.8–52.3) 32.5 (18.5–59.8) 0.49
>65, n (%) 3 (16.7) 1 (10) 1.00
<15, n (%) 5 (27.8) 1 (10) 0.37
Gender, male, n (%) 6 (33.3) 5 (50) 0.44
Bite site 0.12
Hand 11 (61.1) 1 (10)
Forearm 2 (11.1) 3 (30)
Other/unknown 5 (27.8) 6 (60)
Vital signs on admission
SBP (mmHg) 135 (111–156) 130 (125–136) 0.67
BT (°C) 36.9 (36.4–37.1) 36.7 (36.5–36.8) 0.59
Laboratory data
WBC (/mm3) 7,697 (5,398–9,550) 9,000 (7,350–9,750) 0.46
Platelet count (×104/mm3) 23.3 (17.8–30.4) 23.6 (18.0–28.9) 0.88
CK (IU/L) 123 (65–169) 159 (85–190) 0.62
AST (IU/L) 35 (23–51) 28 (22–61) 0.77
Treatment
Antivenom, n (%) 2 (11.1) 4 (40) 0.15
Analgesics, n (%) 5 (27.8) 3 (30) 1.00
Outcome
Hospital admission, n (%) 1 (5.6) 3 (30) 0.12
ICU admission, n (%) 0 (0) 1 (10) 0.36
Data are presented as median (interquartile range, IQR) for continuous variables and n (percentage) for categorical variables.
SBP systolic blood pressure; BT body temperature; WBC white blood cell; CK creatine kinase; AST aspartate aminotransferase.
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and this production started since April 2014.
There are many limitations to this study. A major limi-
tation is that it had a retrospective design and a relatively
small sample size. Selection bias may also have occurred
because not all cases were collected. We conducted the
current survey with 470 sentinel medical institutions ori-
ginally used for the national surveillance for infections of
antimicrobial resistant bacteria and severe influenza with
response rate of 63.2%. Many cases may have remained
undiagnosed or misdiagnosed because of the unfamiliarTable 3 Cases administered with antivenom
Case Age Gender Symptoms Reason for administration
1 6 M Localized N/A
2 14 M Systemic Systemic symptoms (numbness on the
3 36 M Systemic Systemic symptoms (headache)
4 59 F Systemic Systemic symptoms (systemic pain, diz
5 68 F Localized Patient’s wish
6 87 F Systemic Systemic symptoms (severe systemic p
N/A not applicable.symptoms presented by RBS bites. Given the number of
patients included, multivariate analysis (logistic regres-
sion model) could not performed to identify the factors
associated with developing systemic symptoms.
Conclusions
Approximately one third of cases developed systemic
symptoms and antivenom was administered effectively
and safely in severe cases. Further research is required
to identify clinically applicable indications for antivenom
use.Premedication Adverse effect Clinical effect
Antihistamine None N/A
abdomen) Antihistamine None Pain relief
None Flushing on the face Pain relief
ziness, nausea) Epinephrine None Symptoms relief
Antihistamine None N/A
ain) None None Pain relief
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